We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Tricida Inc | NASDAQ:TCDA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.108 | 0.104 | 0.105 | 0 | 01:00:00 |
Tricida Fourth Quarter and Year-End 2020 Conference Call | ||
Thursday, February 25, 2021 4:30 pm Eastern Time | ||
Webcast: | IR.Tricida.com | |
Dial-in: | (800) 733-2954 | |
International: | (847) 413-3731 | |
Conference ID: | 50111253 | |
A replay of the webcast will be available on Tricida’s website approximately two hours following the completion of the call and will be available for up to 90 days following the presentation.
About Tricida
Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.
For more information about Tricida, please visit www.Tricida.com.
Contact: Jackie CossmonTricida, Inc.Senior Vice President of Investor Relations and CommunicationsIR@Tricida.com
Source: Tricida, Inc.
1 Year Tricida Chart |
1 Month Tricida Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions